Cargando…

Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents

Attention deficit hyperactivity disorder (ADHD) is the most common psychiatric illness in children and adolescents. Several stimulant medications, such as methylphenidate and amphetamine derivatives, are available to treat ADHD in pediatric patients. Nonstimulant medications are more preferred by so...

Descripción completa

Detalles Bibliográficos
Autor principal:	Bello, Nicholas T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494608/ https://www.ncbi.nlm.nih.gov/pubmed/26170637 http://dx.doi.org/10.2147/PPA.S73167

Ejemplares similares

Pharmacokinetics of Coadministration of Guanfacine Extended Release and Methylphenidate Extended Release
por: Roesch, Benno, et al.
Publicado: (2013)

Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe
por: Huss, Michael, et al.
Publicado: (2015)

Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate
por: Roesch, Benno, et al.
Publicado: (2013)

Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment
por: Huss, Michael, et al.
Publicado: (2016)

Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder
por: Martinez-Raga, Jose, et al.
Publicado: (2015)

Once-daily treatment of ADHD with guanfacine: patient implications
por: Strange, Brandon C
Publicado: (2008)

Metabolite profiling of guanfacine in plasma and urine of healthy Japanese subjects after oral administration of guanfacine extended‐release tablets
por: Inoue, Yuji, et al.
Publicado: (2019)

Delayed Signs and Symptoms of Extended Release Guanfacine Overdose in Two Adolescent Patients: Implications of Monitoring on the Psychiatry Unit
por: Mishra, Sanskriti, et al.
Publicado: (2022)

Treatment Patterns, Health Care Resource Utilization, and Health Care Cost Associated with Atypical Antipsychotics or Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Quebec, Canada
por: Lachaine, Jean, et al.
Publicado: (2019)

Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents
por: Sikirica, Vanja, et al.
Publicado: (2012)

Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison
por: Joseph, Alain, et al.
Publicado: (2017)

Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug–Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers
por: Li, Aiqun, et al.
Publicado: (2017)

A retrospective medical chart review of clinical outcomes in children and adolescents with attention-deficit/hyperactivity disorder treated with guanfacine extended-release in routine Canadian clinical practice
por: van Stralen, Judy, et al.
Publicado: (2021)

Comparative Efficacy of Guanfacine Extended Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Applying Matching-Adjusted Indirect Comparison Methodology
por: Sikirica, Vanja, et al.
Publicado: (2013)

Correction to: Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug–Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers
por: Li, Aiqun, et al.
Publicado: (2017)

Evaluating Guanfacine Hydrochloride in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adult Patients: Design, Development and Place in Therapy
por: Ota, Toyosaku, et al.
Publicado: (2021)

Guanfacine monotherapy for ADHD/ASD comorbid with Tourette syndrome: a case report
por: Okazaki, Kosuke, et al.
Publicado: (2019)

The behavioural response of mice lacking NK(1) receptors to guanfacine resembles its clinical profile in treatment of ADHD
por: Pillidge, Katharine, et al.
Publicado: (2014)

Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD
por: Lachaine, Jean, et al.
Publicado: (2016)

Guanfacine treatment improves ADHD phenotypes of impulsivity and hyperactivity in a neurofibromatosis type 1 mouse model
por: Lukkes, J. L., et al.
Publicado: (2020)

Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial
por: Stein, Mark A., et al.
Publicado: (2015)

Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer’s Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments
por: Hoang, Karen, et al.
Publicado: (2022)

Cost-utility analysis of methylphenidate treatment for children and adolescents with ADHD in Brazil
por: Maia, Carlos R., et al.
Publicado: (2015)

Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study
por: Iwanami, Akira, et al.
Publicado: (2020)

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson’s disease
por: Hametner, Eva-Maria, et al.
Publicado: (2012)

Guanfacine for the Treatment of Cognitive Disorders: A Century of Discoveries at Yale
por: Arnsten, Amy F.T., et al.
Publicado: (2012)

Stressing the potential of guanfacine as a treatment for cocaine use disorder
por: Lustberg, Daniel, et al.
Publicado: (2020)

Guanfacine as an effective drug for the treatment of tic disorder. Case report
por: Del Sol Calderon, P., et al.
Publicado: (2021)

Correction to: Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study
por: Iwanami, Akira, et al.
Publicado: (2020)

Attention deficits following ADEM ameliorated by guanfacine
por: Singh-Curry, Victoria, et al.
Publicado: (2010)

Effect of Enteral Guanfacine on Dexmedetomidine Use in the ICU
por: Fetters, Megan B., et al.
Publicado: (2022)

Lisdexamfetamine in combination with guanfacine as an effective treatment in the management of behavioral disturbances in patients with Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). Case report
por: Del Sol Calderon, P., et al.
Publicado: (2023)

Authors’ Reply to Alatorre et al.: “Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison”
por: Erder, M. Haim, et al.
Publicado: (2013)

Characteristics of ADHD Symptom Response/Remission in a Clinical Trial of Methylphenidate Extended Release
por: Weiss, Margaret, et al.
Publicado: (2019)

Assessing Palatability of a New Amphetamine Extended-Release Tablet Formulation for the Treatment of ADHD
por: Pardo, Antonio, et al.
Publicado: (2021)

The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG)
por: Coghill, David, et al.
Publicado: (2021)

An in vitro evaluation of guanfacine as a substrate for P-glycoprotein
por: Gillis, Nancy K, et al.
Publicado: (2011)

T47. GUANFACINE AUGMENTATION OF ATTENTIONAL FUNCTIONING IN THE SCHIZOPHRENIA SPECTRUM
Publicado: (2020)

A Retrospective Analysis of Guanfacine for the Pharmacological Management of Delirium
por: Jiang, Shixie, et al.
Publicado: (2023)

Clinically Meaningful Improvements in Early Morning and Late Afternoon/Evening Functional Impairment in Children with ADHD Treated with Delayed-Release and Extended-Release Methylphenidate
por: Wilens, Timothy E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8velp70m32h3s4gaqn1ngevsv3